Cargando…
The Smartphone App haMSter for Tracking Patient-Reported Outcomes in People With Multiple Sclerosis: Protocol for a Pilot Study
BACKGROUND: Treatment and monitoring decisions in people with multiple sclerosis (MS) are based commonly on clinician-reported outcomes. These reflect physical and radiological disease activity and are the most relevant endpoints in clinical trials. Over the past few years, the number of studies eva...
Autores principales: | Altmann, Patrick, Hinterberger, Werner, Leutmezer, Fritz, Ponleitner, Markus, Monschein, Tobias, Zrzavy, Tobias, Zulehner, Gudrun, Kornek, Barbara, Lanzenberger, Rupert, Berek, Klaus, Rommer, Paulus Stefan, Berger, Thomas, Bsteh, Gabriel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140378/ https://www.ncbi.nlm.nih.gov/pubmed/33960949 http://dx.doi.org/10.2196/25011 |
Ejemplares similares
-
Feasibility of a smartphone app to monitor patient reported outcomes
in multiple sclerosis: The haMSter interventional trial
por: Altmann, Patrick, et al.
Publicado: (2022) -
Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis
por: Altmann, Patrick, et al.
Publicado: (2021) -
Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023) -
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023) -
Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis
por: Monschein, Tobias, et al.
Publicado: (2020)